Immunotherapies targeting tau in mouse models of human tauopathies could have disease-modifying effects. In this issue of Neuron, Yanamandra et al. (2013) use tau antibodies, which effectively block tau seeding in culture, to attenuate tauopathy and improve cognition in mutant tau mouse models.
Alzheimer's disease (AD) is pathologically characterized by the presence of both extracellular Ab deposits and intracellular deposits of tau in the brain. Multiple lines of evidence indicate that accumulation and aggregation of both proteins plays a pivotal role in disease, and thus both Ab and tau have been the primary foci of efforts to develop disease-modifying therapies for AD. Tau inclusion pathology also is the primary pathological hallmark of several other neurodegenerative disorders such as progressive supranuclear palsy and Pick's disease. In addition, mutations in tau that result in neurofibrillary pathology and neurodegeneration can cause FTLD-17t. Thus, tau is a major therapeutic target in AD and in neurodegenerative diseases that are collectively referred to as tauopathies.
Following the pioneering preclinical studies by Schenk and colleagues demonstrating the preclinical efficacy of active and passive immunotherapy targeting Ab, there has been increasing interest in developing immunotherapies to treat AD and other neurodegenerative proteinopathies including human tauopathies. Though many questions remain regarding mechanisms of action of antiAb immunotherapies and optimal trial design to evaluate efficacy in humans, there has been rapid advancement of these therapies into human trials (Golde et al., 2009) , although initial therapeutic trials have not shown significant evidence for efficacy in humans with mild to moderate AD (Golde et al., 2011) .
Following peripheral antibody administration, only a small fraction is found in the brain (0.1% of the serum levels). Thus, initial Ab immunotherapy studies were met with some skepticism regarding how such a small amount of antibody could have robust effects on brain Ab deposition. Nevertheless, because Ab is a normally secreted protein and primarily deposits outside of cells in the brain parenchyma, the concept that an antiAb antibody present at low levels in the brain interstitial fluid could affect Ab deposition was at least partly accepted by the field. In contrast, when proof-ofconcept studies emerged suggesting that active and passive anti-tau immunotherapy might also attenuate tau pathology in mouse models, there was substantial skepticism of how extracellular anti-tau antibodies could target intracellular tau inclusions (reviewed in Gu and Sigurdsson, 2011) . Moreover, given the variance in degree of pathology in tau mouse models and the rather modest effects seen in initial studies, skepticism remained regarding the potential therapeutic utility of antitau immunotherapy.
In the current study, Yanamandra et al. (2013) provide in vivo preclinical data in a P301S mouse model of tauopathy showing that direct chronic infusion of select anti-tau antibodies is efficacious. Not only did select tau antibodies suppress tau pathology, they also improved cognitive function. Moreover, by selecting tau antibodies based on their empirical ability to block exogenous seeding of tau inclusions in cell culture, Yanamandra et al. (2013) established a method to rapidly identify potentially efficacious antibodies for in vivo testing. The most effective antibodies in vitro were also the most effective at attenuating pathology in vivo. This is important as it supports Yanamandra et al. (2013) 's assertion that the most likely mechanism of action is targeting tau released from cells (see Figure 1 ) that is potentially capable of nucleating pathology in neighboring cells (Frost et al., 2009 ).
As Yanamandra et al. (2013) discuss, there are other plausible mechanisms by which anti-tau antibodies could attenuate pathology and additional study will be important. For example, if an antibodytau complex gains entry to the cell or the antibody gains entry and then binds intracellular tau, the complex could be recognized by TRIM21-a protein that contains the highest affinity IgG heavy chain (Fc) binding domain of any mammalian protein and a ubiquitin ligase domain (McEwan et al., 2011 )-thus targeting the complex for degradation by the proteosome. There is also evidence that neurons have Fc receptors, which could play a role in internalization of tau antibodies (Mohamed et al., 2002) . Although Yanamandra et al. (2013) did not detect intraneuronal antitau IgGs, others have reported the presence of tau antibodies in neurons following immunotherapy.
If, as the current data would strongly suggest, anti-tau antibodies bind extracellular tau and block uptake of seedingcompetent tau assemblies into the cell, then there are several interrelated and therapeutically relevant issues that need further clarification. For instance, why does antibody engagement of extracellular tau block its ability to seed intracellular inclusion pathology? It is not clear why those antibodies most effective at blocking tau seeding in culture were also the most effective antibodies in vivo. The most effective antibodies may be those that effectively bind the form of tau that is most capable of seeding. However, as no one has identified the precise structural nature of the ''seed'' for any protein that promotes pathological conformational templating, this presumption remains unproven. Interestingly, all of the anti-tau antibodies in the current study with in vivo efficacy also had high affinity for tau and bound distinct linear epitopes, suggesting that they do not bind specific tau conformers responsible for seeding. This is potentially important as evidence emerges that many amyloid proteins may have specific conformers or strains, which might limit efficacy of a conformation-specific antibody.
The fate of the anti-tau antibody tau complex is also unclear. There are two likely, nonexclusive possibilities: the complex is rapidly exported from the brain to the plasma, as has been observed for anti-Ab antibody-Ab complexes; or it binds to microglial FcR and is subsequently degraded by these cells (Levites et al., 2006; Schenk et al., 1999) . If an antibody-tau complex formed in the CNS can be detected in the plasma, this would be a major advance as it would provide a peripheral marker for target engagement of a tau-based immunotherapy.
The relative contribution of seeding to other mechanisms underlying tau pathology is also an unexplored issue. As discussed in a recent review, ''spread'' of inclusion pathology in CNS proteinopathies is likely to result from a combination of mechanisms that includes cell-autonomous intrinsic disruption of proteostasis and two non-cell-autonomous mechanisms-seeding from extracellular tau and induction of a toxic environment induced either by extracellular tau acting as an inflammogen or by a response to intracellular inclusion pathology that could promote aggregate formation (Golde et al., 2013) . Unless tau antibodies actually do target tau directly in the cell, an anti-tau antibody would presumably only target the non-cell-autonomous mechanisms. Though animal modeling data suggest that non-cell-autonomous seeding may play a major role in spread in some mouse tauopathy models (de Calignon et al., 2012; Liu et al., 2012) , the extent to which it contributes to spread in human tauopathies is unknown. If in humans, as suggested by spatiotemporal progression of tau pathology, seeding is a major pathway of pathology spread (Braak and Braak, 1991) , then tau antibodies should prove effective. If the majority of pathology develops via an intrinsic disruption of proteostasis or a toxic environment that is independent of extracellular tau, then tau immunotherapies may prove less effective.
One of the nuances of the current study is that the antibodies were chronically infused into the ventricles by osmotic pumps. Yanamandra et al. (2013) designed the infusions to produce CNS antibody levels similar to what are achieved following peripheral dosing studies, thereby circumventing the issue of low levels of antibody getting into the CNS. All antibodies almost certainly cycle between the plasma into CNS and rapid cycling can result in reasonably high CNS exposure of the total antibody dosed (Golde et al., 2009 ). Thus, tau may be a better target for peripheral immunotherapy then Ab. Unlike Ab, tau is present at undetectable levels in plasma; thus, there is no significant peripheral pool of tau to bind to the antibody before it reaches its target in the CNS. In addition, the levels of extracellular interstitial fluid and CSF tau are quite low relative to Ab (Yamada et al., 2011) . Even small amounts of antibody could significantly deplete this pool.
Irrespective of whether the antibodies work when injected peripherally, it is important to consider that direct cerebral administration of antibodies may have potential benefits. Direct infusion would obviate concerns about insufficient CNS exposure. For clinical use, direct infusion would likely dramatically reduce the amount of antibody needed, reducing the cost of therapy and potentially limiting Exogenous pathological tau, presumably released from neurons, ''seeds'' formation of tau aggregates in other neurons and induces an inflammatory response (activated microglia and astrocytes), thereby propagating neuropathology. Anti-tau antibodies probably bind to exogenous pathological tau (including fibrils) and prevent both ''seeding'' and non-cell-autonomous neuroimmune response. The degree to which anti-tau antibodies might also get into neurons and affect spread of tau pathology is not represented here but should be considered.
induction of antibodies against the injected antibody. The potential benefits of direct infusion, however, must be weighed against the invasiveness of the technique. Issues such as timing, duration, and frequency of dosing, as well as safety and tolerability, could critically impact the feasibility of direct administration. Delivery issues will need to be resolved for such therapy to be viable and available to our ever increasing patient population.
The current study will likely bolster ongoing efforts to rapidly move tau immunotherapy toward human trials. The screen developed by Yanamandra et al. (2013) to identify antibodies capable of blocking tau seeding may be transformative, as it provides a method to rapidly select antibodies most likely to work in vivo. A remaining challenge is the ability of tau immunotherapy to alter tau-induced neurodegenerative changes. Given the huge expense associated with AD therapeutics trials and additional expenses incurred when using a biological therapy, it may be well warranted to thoroughly evaluate such immunotherapy in multiple preclinical models before rushing to the clinic. Though many would argue that tau dysfunction and pathology is a secondary but extremely important ''hit'' in AD, whether there is a true temporal distinction between Ab accumulation and tau dysfunction in human brain is still a subject of great debate. Thus, the field should be cautious and ensure that trial design for future anti-tau immunotherapies matches the situations in which preclinical studies show significant efficacy. As there is no clear-cut road map for assessing cognitive or functional changes in the preclinical stages of AD, future clinical studies will need to incorporate biomarkers to track target engagement and provide early indicators of possible therapeutic efficacy. The recent development of imaging-based biomarkers that track the progression of tau pathology in living patients should greatly facilitate the early phase testing of tau immunotherapies and other tau-targeting therapeutics (Maruyama et al., 2013) .
